Identifying stocks to buy and hold for decades rather than months or years can be difficult. The world and the economy are constantly changing, creating risks for long-term investors.

An outside group of experts agreed that the CDC should recommend a new antibody drug that offers protection against RSV for ...

Merck's growing pipeline, with nearly 20 new launches ahead, is set to reshape its portfolio as Keytruda's 2028 patent expiry ...

The most significant recent development for SpringWorks is the agreement by Merck KGaA to acquire the company at $47 per share. This deal values SpringWorks at approximately $3.9 billion in equity ...

Merck is a clear Buy at current valuations for long term, GARP, and dividend-focused investors, balancing between short-term support from its defensive positioning and long-term optionality.

About Merck & Co Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections.

Investing.com -- Merck KGaA (ETR:MRCG) shares fell more than 5% Thursday after the company lowered its full-year outlook, citing weak demand in its Life Science and Electronics units, despite ...

This microcap company with market capitalization of $42.53 million posted a 311.6% year-over-year revenue surge to $24.4 million for the nine months ended Dec. 31, 2024, driven by RxCompound and ...

Global pharmaceutical company Merck (NYSE:MRK) reported Q1 CY2025 results exceeding the market’s revenue expectations, but sales fell by 1.6% year on year to $15.53 billion. The company expects ...

Product mix and operational efficiency haven’t just boosted profits; they’ve expanded margins like a well-placed waistband after Thanksgiving dinner. Looking forward to 2025, Merck expects annual ...